+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type, ALS Type, Distribution Channel, and Country: Trend Outlook and Growth Opportunity

  • ID: 5357404
  • Report
  • June 2021
  • Region: North America
  • 78 pages
  • GMD Research

FEATURED COMPANIES

  • AB Science SA
  • Biogen Inc.
  • BrainStorm Cell Limited
  • Corestem, Inc.
  • F.Hoffmann-La Roche AG
North America amyotrophic lateral sclerosis treatment market is expected to grow by 5.0% annually in the forecast period and reach $270.6 million by 2027 owing to the increasing geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies.



Highlighted with 21 tables and 31 figures, this 78-page report “North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire North America amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:
  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Five Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Country.

Based on Treatment Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
  • Medication
  • Riluzole (Rilutek)
  • Radicava (Edaravone)
  • Tiglutik (Thickened Riluzole)
  • Nuedexta
  • Stem Cell Therapy
  • Other Treatments
Based on ALS Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
  • Sporadic ALS
  • Familial ALS
Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
Geographically, the following national/local markets are fully investigated:
  • U.S.
  • Canada
  • Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):
  • AB Science SA
  • Amylyx Pharmaceuticals Inc.
  • Biogen Inc.
  • Biohaven Pharmaceutical Holding Co., Ltd.
  • BrainStorm Cell Limited
  • Corestem, Inc.
  • F.Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Science SA
  • Biogen Inc.
  • BrainStorm Cell Limited
  • Corestem, Inc.
  • F.Hoffmann-La Roche AG
1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Five Forces Analysis

3 Segmentation of North America Market by Treatment Type
3.1 Market Overview by Treatment Type
3.2 Medication
3.3 Stem Cell Therapy
3.4 Other Treatments

4 Segmentation of North America Market by ALS Type
4.1 Market Overview by ALS Type
4.2 Sporadic ALS
4.3 Familial ALS

5 Segmentation of North America Market by Distribution Channel
5.1 Market Overview by Distribution Channel
5.2 Hospital Pharmacies
5.3 Retail Pharmacies
5.4 Online Pharmacies
5.5 Other Distribution Channels

6 North America Market 2020-2027 by Country
6.1 Overview of North America Market
6.2 U.S.
6.3 Canada
6.4 Mexico

7 Competitive Landscape
7.1 Overview of Key Vendors
7.2 New Product Launch, Partnership, Investment, and M&A
7.3 Company Profiles
  • AB Science SA
  • Amylyx Pharmaceuticals Inc.
  • Biogen Inc.
  • Biohaven Pharmaceutical Holding Co., Ltd.
  • BrainStorm Cell Limited
  • Corestem, Inc.
  • F.Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
List of Tables
Table 1. Snapshot of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027
Table 2. Growth Rate of World GDP, 2020-2022
Table 3. Main Product Trends and Market Opportunities in North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Table 4. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn
Table 5. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, $ mn
Table 6. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn
Table 7. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn
Table 8. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn
Table 9. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn
Table 10. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn
Table 11. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn
Table 12. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn
Table 13. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn
Table 14. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn
Table 15. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn
Table 16. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn
Table 17. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn
Table 18. AB Science SA: Company Snapshot
Table 19. AB Science SA: Business Segmentation
Table 20. AB Science SA: Product Portfolio
Table 21. AB Science SA: Revenue, 2017-2019, $ mn

List of Figures
Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027
Figure 4. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 8. Primary Restraints and Impact Factors of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Five Forces Analysis of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Figure 11. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue
Figure 12. Contribution to North America 2021-2027 Cumulative Revenue by Treatment Type, Value ($ mn) and Share (%)
Figure 13. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, $ mn
Figure 14. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, $ mn
Figure 15. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, $ mn
Figure 16. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue
Figure 17. Contribution to North America 2021-2027 Cumulative Revenue by ALS Type, Value ($ mn) and Share (%)
Figure 18. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, $ mn
Figure 19. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, $ mn
Figure 20. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue
Figure 21. Contribution to North America 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)
Figure 22. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, $ mn
Figure 23. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, $ mn
Figure 24. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, $ mn
Figure 25. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, $ mn
Figure 26. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue
Figure 27. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 28. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn
Figure 29. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn
Figure 30. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Mexico, 2017-2027, $ mn
Figure 31. Growth Stage of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period
Note: Product cover images may vary from those shown
  • AB Science SA
  • Amylyx Pharmaceuticals Inc.
  • Biogen Inc.
  • Biohaven Pharmaceutical Holding Co., Ltd.
  • BrainStorm Cell Limited
  • Corestem, Inc.
  • F.Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll